Momenta Must Face Clot Drug Antitrust Row, 1st Circ. Told

Law360, New York (November 1, 2016, 3:23 PM EDT) -- Misconduct by Momenta before a standard-setting organization that unknowingly led the group to create a standard for a blood-clot drug that requires the use of a company patent should not allow the generics maker to subsequently receive immunity from antitrust claims, generic rival Amphastar told the First Circuit on Monday.

The District of Massachusetts erred by holding in July that the so-called Noerr-Pennington doctrine allowed Momenta Pharmaceuticals Inc. and co-defendant Sandoz Inc. to escape the antitrust claims brought by Amphastar Pharmaceuticals Inc., which alleged that Momenta...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.